Sage Journals: Discover world-class research

Abstract

Objectives

This review on Category A bioweapons is intended to help otolaryngologists (1) understand the concepts of bioterrorism, (2) identify a bioterrorism attack, and (3) recognize specific otolaryngologic symptoms and signs of Category A bioweapons.

Data Sources

PubMed and Medline databases.

Review Methods

Review of current literature regarding Category A agents of biological warfare and their relationships to otolaryngology was performed using PubMed, Medline, and articles written by experts in the field of bioterrorism. Each Category A agent was paired with the term otolaryngology and then paired with epistaxis, sinusitis, airway obstruction, pharyngitis, tonsillitis, hearing loss, otitis media, and lymphadenopathy individually. For the latest accepted treatment and diagnostic strategies, bioterrorism was searched with filters for human studies, English language, and the past 5 years. Titles, abstracts, and papers were read for relevancy.

Conclusion

While the use of bioweapons initially leads to nonspecific symptoms, a high index of suspicion and clustering of abnormal pathology will often lead the astute physician to the correct diagnosis of bioweapons. Some disease presentations of Category A agents (anthrax, smallpox, tularemia, botulism, plague, hemorrhagic fever) will involve the realm of otolaryngology.

Implications for Practice

The head and neck manifestations of a Category A bioweapon attack will require knowledgeable otolaryngologists for prompt diagnosis, treatment, and notification of public authorities. This will help decrease the morbidity and mortality of any potential bioterrorism attack.

Keywords

bioweapons bioterrorism anthrax botulism smallpox tularemia plague hemorrhagic fevers Category A agents

Get full access to this article

View all access options for this article.

References

Hartwig

Burich

Cannon

. Critical challenges ahead in bioterrorism preparedness training for clinicians. Prehosp Disaster Med. 2009;24:47-53.

Inglesby

O’Toole

Henderson

. Anthrax as a biological weapon, 2002: updated recommendations for management. JAMA. 2002;287:2236-2252.

Henderson

Inglesby

Bartlett

. Smallpox as a biological weapon: medical and public health management. JAMA. 1999;281:2127-2137.

Dennis

Inglesby

Henderson

. Tularemia as a biological weapon: medical and public health management. JAMA. 2001;285:2763-2773.

Arnon

Schechter

Iglesby

. Botulinum toxin as a biological weapon: medical and public health management. JAMA. 2001;285:1059-1070.

Inglesby

Dennis

Henderson

. Plague as biological weapon: medical and public health management. JAMA. 2000;283:2281-2290.

Borio

Inglesby

Peters

. Hemorrhagic fever viruses as biological weapons: medical and public health management. JAMA. 2002;287:2391-2405.

Carus

. Bioterrorism and Biocrimes: The Illicit Use of Biological Agents since 1900. Working paper. Washington, DC: Center for Counterproliferation Research, National Defense University; August 1998, revised February 2001. http://www.fas.org/irp/threat/cbw/carus.pdf. Accessed September 10, 2013.

Spencer

Wilcox

. Agents of biological warfare. Rev Med Microbiol. 1993;4:138-143.

10.

Christopher

Cieslak

Pavlin

Eitzen

. Biological warfare: a historical perspective. JAMA. 1997;278:412-417.

11.

Lesho

Dorsey

Bunner

. Feces, dead horses, and fleas: evolution of the hostile use of biological agents. West J Med. 1998;168:512-516.

12.

Jacobs

. The history of biologic warfare and bioterrorism. Dermatol Clin. 2004;22:231-246.

13.

Jernigan

Stephens

Ashford

. Bioterrorism-related inhalational anthrax: first 10 cases reported in the United States. Emerg Infect Dis. 2001;7:933-944.

14.

District of Columbia Hospital Association. Utilization Indicators Calendar Year 2001. http://www.dcha.org/Publications/01Utilization.PDF. Accessed October 1, 2013.

15.

Centers for Disease Control and Prevention. Biological and chemical terrorism: strategic plan for preparedness and response. MMWR Morb Mortl Wkly Rep. 2000;49:1-14.

16.

Center for Counterproliferation Research. Anthrax in America: a chronology and analysis of the fall 2001 attacks (November 2001). http://www.ndu.edu/centercounter/ANTHRAX%20CHRONOLOGY.pdf. Accessed August 15, 2013.

17.

Doganay

Almac

Hanagasi

. Primary throat anthrax: a report of six cases. Scand J Infect Dis. 1986;18:415-419.

18.

Shafazand

Doyle

Ruoss

Weinacker

Raffin

. Inhalational anthrax: epidemiology, diagnosis, and management. Chest. 1999;116:1369-1376.

19.

Varkey

Poland

Cockerill

Smith

Hagen

. Confronting bioterrorism: physicians on the front line. Mayo Clin Proc. 2002;77:661-672.

20.

Wilson

. Clinical manifestations and diagnosis of anthrax (June 2013). http://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-anthrax. Accessed August 4, 2013.

21.

Sirisanthana

Navachareon

Tharavichitkul

. Outbreak of oral-oropharyngeal anthrax: an unusual manifestation of human infection with Bacillus anthracis. Am J Trop Med Hyg. 1984;33:144-150.

22.

Sirisanthana

Nelson

Ezzell

. Serological studies of patients with cutaneous and oral-pharyngeal anthrax from northern Thailand. Am J Trop Med Hyg. 1988;39:575-581.

23.

Wirtschafter

Cherukuri

Benninger

. Anthrax: ENT manifestations and current concepts. Otolaryngol Head Neck Surg. 2002;126:8-13.

24.

Turnbull

PCB

Kamer

. Bacillus. In: Balows

, ed. Manual of Clinical Microbiology. 5th ed. Washington, DC: American Society for Microbiology; 1991:296-303.

25.

Aquino

. Cutaneous manifestations of Category A bioweapons. J Am Acad Dermatol. 2011;65:1213.e1-e15.

26.

Beeching

Dance

DAB

Miller

ARO

Spencer

. Biological warfare and bioterrorism. BMJ. 2002;324:336-339.

27.

Tennyson

Mair

. Smallpox: what every otolaryngologist should know. Otolaryngol Head Neck Surg. 2004;130:323-333.

28.

Darling

Catlett

Huebner

Jarret

. Threats in bioterrorism I: CDC category A agents. Emerg Med Clin North Am. 2002;20:273-309.

29.

Moore

Seward

Lane

. Smallpox. Lancet. 2006;367:425-435.

30.

Cohen

. Bioterrorism: smallpox vaccinations: how much protection remains? Science. 2001;294:985.

31.

Rinaldo

Bradley

Ferlito

. Tularemia in otolaryngology: a forgotten but not gone disease and a possible sign of bio-terrorism. J Laryngol Otol. 2004;118:257-259.

32.

Ockenhouse

. Tularemia. In: Roy

, ed. Physician’s Guide to Terrorist Attack. Totowa, NJ: Humana; 2004:103-110.

33.

Kman

Nelson

. Infectious agents of bioterrorism: a review for emergency physicians. Emerg Med Clin North Am. 2008;26:517-547.

34.

Luotonen

Syrjala

Jokinen

. Tularemia in otolaryngologic practice. Arch Otolaryngol Head Neck Surg. 1986;112:77-80.

35.

Chiu

Yang

Soni

. Pharmacological exploitation of an off-target antibacterial effect of the cyclooxygenase-2 inhibitor celecoxib against Francisella tularensis. Antimicrob Agents Chemother. 2009;53:2998-3002.

36.

Jia

Lee

Clemens

Bowen

Horwitz

. Recombinant attenuated Listeria monocytogenes vaccine expressing Francisella tularensis IglC induces protection in mice against aerosolized type A F. tularensis. Vaccine. 2009;18:1216-1229.

37.

Jia

Lee

Bowen

. A Francisella tularensis live vaccine strain (LVS) mutant with a deletion in capB, encoding a putative capsular biosynthesis protein, is significantly more attenuated than LVS yet induces potent protective immunity in mice against F. tularensis challenge. Infect Immun. 2010;78:4341-4355.

38.

Franz

Jahrling

Friedlander

. Clinical recognition and management of patients exposed to biological warfare agents. JAMA. 1997;278:399-411.

39.

Balali-Mood

Moshiri

Etemad

. Medical aspects of bio-terrorism. Toxicon. 2013;69:131-142.

40.

Martin

Adams

. Neurological aspects of biological and chemical terrorism: a review for neurologists. Arch Neurol. 2003;60:21-25.

41.

Byrne

Smith

. Development of vaccines for prevention of botulism. Biochimie. 2000;82:955-966.

42.

Louie

Heine

VanScoy

. Use of an in vitro pharmacodynamic model to derive a moxifloxacin regimen that optimizes kill of Yersinia pestis and prevents emergence of resistance. Antimicrob Agents Chemother. 2011;55:822-830.

43.

Sun

Roland

Curtiss

III . Developing live vaccines against plague. J Infect Dev Ctries. 2011;5:614-627.

44.

Nakayama

Saijo

. Animal models for Ebola and Marburg virus infections. Front Microbiol. 2013;4:267.

45.

Gire

Stremlau

Andersen

. Epidemiology: emerging disease or diagnosis. Science. 2012;338:750-752.

46.

Lukashevich

. The search for animal models for Lassa fever vaccine development. Expert Rev Vaccines. 2013;12:71-86.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.05 MB

Age of Bioterrorism

Abstract

Objectives

Data Sources

Review Methods

Conclusion

Implications for Practice

Keywords

Get full access to this article

References

Supplementary Material